PE20030043A1 - Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo - Google Patents
Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodoInfo
- Publication number
- PE20030043A1 PE20030043A1 PE2002000455A PE2002000455A PE20030043A1 PE 20030043 A1 PE20030043 A1 PE 20030043A1 PE 2002000455 A PE2002000455 A PE 2002000455A PE 2002000455 A PE2002000455 A PE 2002000455A PE 20030043 A1 PE20030043 A1 PE 20030043A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- activator
- peroxisome
- proliferator
- azol
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 229940125708 antidiabetic agent Drugs 0.000 title abstract 2
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 229940125710 antiobesity agent Drugs 0.000 title 1
- -1 AMINO Chemical class 0.000 abstract 3
- 239000012190 activator Substances 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 210000002824 peroxisome Anatomy 0.000 abstract 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 abstract 1
- 101710088194 Dehydrogenase Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 101100395338 Mus musculus Hmga2 gene Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001761 chlorpropamide Drugs 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 229960004580 glibenclamide Drugs 0.000 abstract 1
- 229960000346 gliclazide Drugs 0.000 abstract 1
- 229960004346 glimepiride Drugs 0.000 abstract 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 abstract 1
- 229960001381 glipizide Drugs 0.000 abstract 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 206010024627 liposarcoma Diseases 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000003614 peroxisome proliferator Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29438001P | 2001-05-30 | 2001-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030043A1 true PE20030043A1 (es) | 2003-02-05 |
Family
ID=23133159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000455A PE20030043A1 (es) | 2001-05-30 | 2002-05-30 | Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20030092736A1 (https=) |
| EP (1) | EP1390363A4 (https=) |
| JP (1) | JP2004536070A (https=) |
| AU (1) | AU2002259306B2 (https=) |
| CA (1) | CA2449160A1 (https=) |
| CZ (1) | CZ20033230A3 (https=) |
| DE (1) | DE02729306T1 (https=) |
| ES (1) | ES2214168T1 (https=) |
| HU (1) | HUP0401504A3 (https=) |
| MX (1) | MXPA03010997A (https=) |
| NO (1) | NO327089B1 (https=) |
| PE (1) | PE20030043A1 (https=) |
| PL (1) | PL367066A1 (https=) |
| TR (1) | TR200400650T3 (https=) |
| TW (1) | TWI235061B (https=) |
| UY (1) | UY27316A1 (https=) |
| WO (1) | WO2002096358A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060167045A1 (en) * | 2002-08-21 | 2006-07-27 | Joanne Waldstreicher | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist |
| EP1424070A1 (en) * | 2002-11-28 | 2004-06-02 | Fournier Laboratories Ireland Limited | Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides |
| SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| US7601756B2 (en) * | 2003-06-06 | 2009-10-13 | Snowden Pharmaceuticals, Llc | Method of treatment for irritable bowel syndrome |
| EP1646628A1 (en) * | 2003-07-08 | 2006-04-19 | Novartis AG | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
| MXPA06003205A (es) * | 2003-09-22 | 2006-06-23 | Ono Pharmaceutical Co | Derivados de acido fenilacetico, proceso para producir el mismo y uso. |
| JP2007526309A (ja) * | 2004-03-02 | 2007-09-13 | アベール ファーマシューティカルズ インコーポレイテッド | 生物活性剤の混合製剤またはキット |
| DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| CN1304393C (zh) * | 2004-07-01 | 2007-03-14 | 中国药科大学 | 取代的吡唑啉酮衍生物及其制备方法与药用组合物 |
| KR100706600B1 (ko) * | 2004-11-25 | 2007-04-12 | 주식회사 엘지생명과학 | ＰＰＡＲ ｇａｍｍａ와 ＰＰＡＲ ａｌｐｈａ의 활성을항진시키는 신규 화합물, 그것의 제조방법, 및 그것을함유한 약제 조성물 |
| WO2006057503A1 (en) * | 2004-11-25 | 2006-06-01 | Lg Life Sciences, Ltd. | NOVEL COMPOUNDS AS AGONIST FOR PPARϜ AND PPARα, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| WO2007058504A1 (en) * | 2005-11-21 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same |
| WO2008127813A1 (en) * | 2007-03-09 | 2008-10-23 | Hiberna Corporation | Hibernation-related genes and proteins, activators and inhibitors thereof and methods of use |
| CA2706727A1 (en) * | 2007-11-29 | 2009-06-11 | Michael S. Mcgrath | Compositions and methods for treating lysosomal disorders |
| JP5444365B2 (ja) * | 2008-10-29 | 2014-03-19 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質 |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN109498622A (zh) * | 2018-12-28 | 2019-03-22 | 成都恒瑞制药有限公司 | 一种氯沙坦钾与罗格列酮组合物及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| US5591862A (en) * | 1993-06-11 | 1997-01-07 | Takeda Chemical Industries, Ltd. | Tetrazole derivatives, their production and use |
| PL351470A1 (en) * | 1999-04-28 | 2003-04-22 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
| ATE260912T1 (de) * | 1999-09-08 | 2004-03-15 | Glaxo Group Ltd | Oxazol ppar antagonisten |
| IL149493A0 (en) * | 1999-11-10 | 2002-11-10 | Takeda Chemical Industries Ltd | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| WO2002076959A1 (en) * | 2001-03-23 | 2002-10-03 | Takeda Chemical Industries, Ltd. | Five-membered heterocyclic alkanoic acid derivative |
-
2002
- 2002-05-22 US US10/153,454 patent/US20030092736A1/en not_active Abandoned
- 2002-05-23 ES ES02729306T patent/ES2214168T1/es active Pending
- 2002-05-23 EP EP02729306A patent/EP1390363A4/en not_active Withdrawn
- 2002-05-23 CZ CZ20033230A patent/CZ20033230A3/cs unknown
- 2002-05-23 MX MXPA03010997A patent/MXPA03010997A/es active IP Right Grant
- 2002-05-23 CA CA002449160A patent/CA2449160A1/en not_active Abandoned
- 2002-05-23 AU AU2002259306A patent/AU2002259306B2/en not_active Ceased
- 2002-05-23 TR TR2004/00650T patent/TR200400650T3/xx unknown
- 2002-05-23 WO PCT/US2002/016633 patent/WO2002096358A2/en not_active Ceased
- 2002-05-23 HU HU0401504A patent/HUP0401504A3/hu unknown
- 2002-05-23 JP JP2002592871A patent/JP2004536070A/ja active Pending
- 2002-05-23 PL PL02367066A patent/PL367066A1/xx not_active Application Discontinuation
- 2002-05-23 DE DE0001390363T patent/DE02729306T1/de active Pending
- 2002-05-24 TW TW091111100A patent/TWI235061B/zh not_active IP Right Cessation
- 2002-05-30 UY UY27316A patent/UY27316A1/es not_active Application Discontinuation
- 2002-05-30 PE PE2002000455A patent/PE20030043A1/es not_active Application Discontinuation
-
2003
- 2003-11-28 NO NO20035312A patent/NO327089B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03010997A (es) | 2004-02-27 |
| NO327089B1 (no) | 2009-04-20 |
| JP2004536070A (ja) | 2004-12-02 |
| WO2002096358A3 (en) | 2003-03-27 |
| CA2449160A1 (en) | 2002-12-05 |
| DE02729306T1 (de) | 2004-08-26 |
| EP1390363A4 (en) | 2011-01-05 |
| TR200400650T3 (tr) | 2004-06-21 |
| HUP0401504A2 (hu) | 2004-11-29 |
| WO2002096358A2 (en) | 2002-12-05 |
| PL367066A1 (en) | 2005-02-21 |
| HUP0401504A3 (en) | 2008-05-28 |
| UY27316A1 (es) | 2002-12-31 |
| NO20035312D0 (no) | 2003-11-28 |
| ES2214168T1 (es) | 2004-09-16 |
| TWI235061B (en) | 2005-07-01 |
| EP1390363A2 (en) | 2004-02-25 |
| US20030092736A1 (en) | 2003-05-15 |
| CZ20033230A3 (cs) | 2004-02-18 |
| AU2002259306B2 (en) | 2007-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030043A1 (es) | Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo | |
| PE20091014A1 (es) | Compuestos espiro y uso farmaceutico de los mismos | |
| PE20001646A1 (es) | BIFENILO QUE CONTIENEN COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE aP2 | |
| ES2526463T3 (es) | Exendina para el tratamiento de la diabetes y la reducción del peso corporal | |
| PE20011056A1 (es) | Acidos ariloxiaceticos para la diabetes y trastornos de los lipidos | |
| PY0314531A (es) | Preparaciones acidas de insulina con estabilidad mejorada | |
| ES2039773T3 (es) | Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus. | |
| ECSP034848A (es) | Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes | |
| AR015358A1 (es) | Antagonistas de la endotelina: n-[[2'-[[(4,5-dimetil-3-isoxazolil)amino]sulfonil]-4-(2-oxazolil)[1,1'-bifenil]-2-il]metil]-n,3,3-trimetilbutanamida yn-(4,5-demitil-3-isoxazolil)-2'-[(3,3-dimetil-2-oxo-1-pirrolidinil)metil]-4'-(2-oxazolil)[1,1'-bifenil]-2-sulfonamida y sales de los mismos y las compo | |
| CO5650227A2 (es) | Derivados del acido propionico utiles en desordenes lipidicos | |
| CO6150170A2 (es) | Derivados de 1-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio | |
| ES2092890T3 (es) | Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson. | |
| WO2001012187A3 (en) | Benzoic acid derivatives and their use as ppar receptor agonists | |
| PE20040655A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen | |
| RU2005141226A (ru) | Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью | |
| PE20081557A1 (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| PA8562801A1 (es) | Nuevos derivados de pirido (2,1-a) isoquinolina | |
| MXPA04006003A (es) | Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano. | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| BR0302584A (pt) | Combinação de brimonidina e timolol para uso oftálmico tópico | |
| PE20030989A1 (es) | Derivados de tiazol y oxazol que modulan la actividad de ppar | |
| PE20100733A1 (es) | Derivados de tiadiazolidinona como inhibidores de ptpasas | |
| EP1543158A4 (en) | REGULATED APTAMER THERAPEUTICS | |
| NO890529D0 (no) | Oksazolidin-2-on-derivater som hypoglycemiske midler. | |
| UY29802A1 (es) | Análogos de la feniletilamina y su uso en el tratamiento del glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |